Acquisition

Five things for pharma marketers to know: Friday, April 24

Five things for pharma marketers to know: Friday, April 24

By

An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo

Five things for pharma marketers to know: Thursday, April 23

Five things for pharma marketers to know: Thursday, April 23

By

Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales

Everyday Health buys rare-disease agency Cambridge BioMarketing

Everyday Health buys rare-disease agency Cambridge BioMarketing

By

The $38-million deal expands the reach of rare-disease campaigns.

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

By

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

Endo makes better offer for Salix

Endo makes better offer for Salix

By

The company argues its offer for Salix is superior to the terms offered by serial acquirer Valeant.

Imbruvica eases AbbVie's patent worries

Imbruvica eases AbbVie's patent worries

By

AbbVie's $21-billion bid to acquire Pharmacyclics may insulate the drugmaker from the impact of impending Humira biosimilars.

Five things for pharma marketers to know: Thursday, March 5

Five things for pharma marketers to know: Thursday, March 5

By

AbbVie nabs Pharmacyclics for $21 billion, Mallinckrodt makes a Pfizer-Hospira style acquisition, and the National Cancer Institute's director resigns

Five things for pharma marketers to know: Wednesday, February 18

Five things for pharma marketers to know: Wednesday, February 18

By

Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan's name and Sanofi enters an auto-immune disease collaboration.

Pfizer's Hospira deal shores up established product division

Pfizer's Hospira deal shores up established product division

By

Pfizer said the $17-billion decision to acquire Hospira will not affect the timeline of its divide-or-stay-whole decision.

Five things for pharma marketers to know: Tuesday, January 6

Five things for pharma marketers to know: Tuesday, January 6

By

Pfizer continues to scoop up vaccine assets, Dendreon heads to auction with no lead bidder, Genentech and 23andMe will take on the Parkinson's genome.

Merck buys Swiss biotech

The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million

Five things for pharma marketers to know: Monday, December 8

Five things for pharma marketers to know: Monday, December 8

By

Merck buys up Cubist in an $8.4B deal, a jury sides with AstraZeneca in a generic Nexium lawsuit and the NYT finds a correlation between Genentech payments and Lucentis prescriptions.

Actavis, Sanofi reportedly spar for Omega

Bloomberg reports that the race to merge with Omega also includes privately-held Boehringer Ingelheim and Perrigo.

Valeant-Allergan duel continues

Valeant indicated in its third-quarter earnings call that it expects to increase its bid for Allergan.

Five things for pharma marketers to know: Friday,  October 17

Five things for pharma marketers to know: Friday, October 17

By

Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.

AbbVie-free Shire could open new opportunities

AbbVie-free Shire could open new opportunities

By

AbbVie's board is encouraging shareholders to kill the Shire acquisition, and analysts say a breakup would still leave Shire in a strong position.

AbbVie reconsiders Shire

AbbVie reconsiders Shire

By

AbbVie is thinking about modifying or walking away from its offer to buy Dublin's Shire. A breakup would cost the Illinois company over $1.6 billion.

Acorda's $525M Civitas buy opens Parkinson's pipeline

Acorda's $525M Civitas buy opens Parkinson's pipeline

By

The all-cash deal gives Acorda access to an experimental inhaled Parkinson's treatment that is meant to help patients when medication levels dip and symptoms surface.

Auxilium turns down Endo, leaves door open

Auxilium turns down Endo, leaves door open

By

The Chesterbrook, PA, drug manufacturer announced Monday Endo's unsolicited $2.2-billion bid undervalued the company.

Endo makes $2.2B bid for Auxilium

Endo makes $2.2B bid for Auxilium

By

Endo's timing also comes as Auxilium has committed to reorganizing and merging with Canada's QLT.

Sanofi wants greater MS role

The plan is to bring in-house products to the market as well as through acquisitions.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.

The Planning Shop joins Omnicom

The London healthcare brand and research agency will be part of Omnicom's DAS Group.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

By

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, August 27

By

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.

Roche spends $8.3B for lung drug

Roche spends $8.3B for lung drug

By

Roche has beat out rumored competitors GlaxoSmithKline and Sanofi in a run-off to acquire California biotech InterMune.

Five things for pharma marketers to know: Monday, August 25

Five things for pharma marketers to know: Monday, August 25

By

Roche backs away from Chugai but embraces InterMune, Merck rumored on track to score first PD-1 approval, a new Ebola strain may have surfaced and JNJ scoops up experimental anti-TNF.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

InterMune joins M&A fray

GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters